DPP4 and type 2 diabetes mellitus: In conclusion, sotagliflozin seems to represent a promising treatment for both type 1 and type 2 diabetes, either alone or in combination with metformin or DPP-4 inhibitors in type 2 diabetes or, with an adequate insulin protocol, in type 1 diabetes.